Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
It is accepted that giving higher doses of chest radiation in as short a time span as possible improves chances of cure. In this study, the investigators propose to give an increased dose of chest radiotherapy for limited stage small cell lung cancer patients using a strategy of giving a slightly higher daily dose of radiotherapy than normal. The investigators hypothesize that our proposed chest radiotherapy dose will improve 2-year overall survival rates in patients with limited stage small cell lung cancer.
Condition or disease
Lung NeoplasmSmall Cell Carcinoma
Radiation: Hypofractionated Chest Radiotherapy
The ideal chest radiotherapy dose/fractionation scheme for limited stage small cell lung cancer is undefined. Strategies of radiotherapy dose intensification with minimization of overall treatment time are felt to improve cure rates for LS-SCLC. Hypofractionation (giving higher than standard daily doses) facilitates both of these goals. In this study, we propose to use a dose escalated hypofractionated regimen of chest radiotherapy for patients with LS-SCLC.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
limited stage small cell lung cancer
adequate pulmonary function test (FEV1 >1.0 L, DLCO >50%)
signed study consent
age at least 18 years
Karnofsky performance status as least 70%
eligible to receive standard concurrent small cell cancer chemotherapy
extensive stage disease
mixed non small cell and small cell histology
inadequate pulmonary function tests
not eligible for concurrent chemotherapy
subtotal or total tumor resection
previous chest/neck radiotherapy
prior or concurrent malignancy except non-melanomatous skin unless disease free for last 5 years
prior chemotherapy for another malignancy
patients with myocardial infarction within the preceding 6 months of symptomatic heart disease, including, angina, congestive heart failure, uncontrolled arrhythmias